Your search for apixaban returned 47 results

For patients initiating oral anticoagulant therapy, the incidence of hospitalization for upper gastrointestinal bleeding is highest and lowest with rivaroxaban and apixaban, respectively.

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

No differences seen in fracture risk in head-to-head comparisons of direct oral anticoagulants

Findings seen among older patients with incident atrial fibrillation receiving warfarin or apixaban

Risk up with amiodarone vs flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban.

Study of newer medications finds 16 percent receive too much or too little

Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.

Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes

Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.

Bolus plus two-hour infusion of andexanet alfa cuts antifactor Xa activity by 92 percent